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 Abstract 
Mutations in mitochondrial DNA (mtDNA) occur at high frequency in human tumors, 
but whether these mutations alter tumor cell behavior has been unclear. We used 
cytoplasmic hybrid (cybrid) technology to replace the endogenous mtDNA in a mouse 
tumor cell line that was poorly metastatic with mtDNA from a cell line that was highly 
metastatic – and vice and versa. Using assays of metastasis in mice, we found that the 
recipient tumor cells acquired the metastatic potential of the transferred mtDNA. The 
mtDNA conferring high metastatic potential contained G13997A and 13885insC 
mutations in the gene encoding NADH dehydrogenase subunit 6 (ND6). These 
mutations produced a deficiency in respiratory complex I activity and were associated 
with overproduction of reactive oxygen species (ROS). Pretreatment of the highly 
metastatic tumor cells with ROS scavengers suppressed their metastatic potential in 
mice. These results indicate that mtDNA mutations can contribute to tumor 
progression by enhancing the metastatic potential of tumor cells. 
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Because most chemical carcinogens bind preferentially to mtDNA rather than to nuclear 
DNA (1-3), mtDNA is considered to be their major cellular target. It has been hypothesized 
that the resultant somatic mutations in mtDNA play a causal role in oncogenic 
transformation (3). Many subsequent studies have supported the idea of preferential 
accumulation of somatic mutations in tumor mtDNAs (4-9) and their contribution to tumor 
growth (10, 11). However, the apparent high frequency of mtDNA mutations in tumors 
could simply be due either to their stochastic accumulation (12, 13) or to laboratory errors 
(14). Moreover, if mtDNA mutations induce oncogenic transformation, all the offspring of 
a mother carrying such mutations should develop tumors due to the maternal inheritance of 
mtDNA (15, 16), but no bias toward maternal inheritance of tumor development has been 
reported. Nonetheless, it remains possible that mtDNA mutations are involved at a later 
stage of tumorigenesis – for example, in the development of metastatic potential. Recent 
studies demonstrated that dysfunction of the tricarboxylic acid cycle (TCA cycle) caused by 
mutations in nuclear DNA controls tumor phenotypes by the induction of a pseudo-hypoxic 
pathway under normoxic conditions (17-19).  However, there has been no evidence of the 
involvement of mtDNA mutations in the development of metastatic potential or in the 
regulation of the pseudo-hypoxic pathway, because of the difficulty of excluding possible 
involvement of nuclear DNA mutations in these processes (20).  
Here we have examined the role of pathogenic mtDNA mutations in the development 
of tumor cell metastasis by studying two mouse tumor cell lines with different metastatic 
potentials (low metastatic P29 and high metastatic A11 cells), that originated from Lewis 
lung carcinoma (Table S1; 21-23). We compared mitochondrial respiratory function by 
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estimating the activities of respiratory complexes, and found that P29 cells had normal 
activities, whereas A11 cells showed reduced activity of complex I (NADH dehydrogenase) 
(Fig. 1A). Complex I defects were also observed in high metastatic fibrosarcoma B82M 
cells, but not in high metastatic colon adenocarcinoma LuM1 cells (Fig. 1A), suggesting 
that all metastatic tumors are not always associated with complex I defects.  
Since complex I consists of subunits encoded by both nuclear DNA and mtDNA (24), 
it was necessary to determine which genome, nuclear or mitochondrial, was responsible for 
the complex I defects, and whether the complex I defects were responsible for the high 
metastatic potential. We addressed these issues by complete reciprocal exchange of 
mtDNAs between P29 and A11 cells by means of cell fusion to isolate trans-mitochondrial 
cybrids (Table S2, Fig. S1A), and examined whether complex I defects and metastatic 
potentials were co-transferred with the mtDNA. The results showed that complex I activity 
decreased in the cybrids with A11 mtDNA, whereas those with P29 mtDNA showed 
normal activity, irrespective of whether their nuclear DNAs were derived from P29 or A11 
cells (Fig. 1B). Thus, complex I defects in the cybrids with A11 mtDNA appear to result 
from pathogenic mutations in their mtDNA, not in their nuclear DNA. We then examined 
the metastatic potential of the cybrids by inoculating them into a tail vein (to test 
“experimental” metastasis) and under the skin (to test “spontaneous” metastasis) of 
C57BL/6 mice, and counting the number of nodules formed in the lung. Cybrids with A11 
mtDNA acquired high metastatic potential, whereas cybrids with P29 mtDNA lost 
metastatic potential (Table S2). These observations suggest that complex I defects and high 
metastatic potential are transferred simultaneously with the transfer of mtDNA from the 
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A11 cells, whereas normal complex I activity and low metastatic potential are transferred 
simultaneously with the transfer of mtDNA from P29 cells. The mtDNA of A11 cells is 
therefore likely to harbour a mutation(s) responsible for complex I defects and metastasis. 
We next examined whether these findings could be generalized to additional tumor 
cell lines. In these experiments, we transferred mtDNA from A11 cells into fibrosarcoma 
B82 cells with low metastatic potential and normal complex I activity, resulting in isolation 
of B82mtA11 cybrids (Table S2). Conversely we transferred mtDNA from B82M cells, 
which are derived from B82 cells but express high metastatic potential and complex I 
defects, into low metastatic P29 cells, resulting in isolation of P29mtB82M cybrids. Both 
B82mtA11 and P29mtB82M cybrids acquired complex I defects (Fig. 1C) and high 
metastatic potential (Table S2), suggesting the co-transfer of these phenotypes and the 
mtDNAs from high to low metastatic cells of different tumor types. Notably, transfer of 
mtDNA from high metastatic A11 and B82M cells into non-transformed NIH3T3 cells did 
not induce tumorigenicity and metastatic potential in the resultant NIHmtA11 and 
NIHmtB82M cybrids (Table S2, Fig. S2A). Thus, pathogenic mtDNA mutations that 
induce complex I defects are present in A11 and B82M cells and control development of 
metastases; however, these mutations do not control the development of tumorigenicity and 
metastasis, at least in non-transformed NIH3T3 cells. 
To identify the pathogenic mtDNA mutations that induced complex I defects and 
high metastatic potential in A11 and B82M cells, we compared the whole mtDNA 
sequences between P29 and A11 cells, and between B82 and B82M cells. We conclude that 
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a missense G13997A mutation in the A11 cells and a frame-shift 13885insC mutation in the 
B82M cells, both within the ND6 (NADH dehydrogenase subunit 6) gene, are the 
pathogenic mutations that induce complex I defects, since these are the only mutations 
exclusively observed in the mtDNA of the high metastatic A11 cells and B82M cells (Table 
1). Restriction enzyme digestion of the PCR products amplified using mismatched primers 
suggests complete and reciprocal replacement of parental mtDNAs in our cybrids (Fig. S3).  
We next explored how the mutated mtDNA and resultant complex I defects regulate 
metastasis. Since complex I defects may lead to overproduction of ROS (24, 25), we 
estimated the amounts of ROS (Fig. S4), and found that the cybrids with the mutated 
mtDNA from A11 cells showed enhanced ROS production, whereas the cybrids without the 
mutated mtDNA from P29 cells did not (Fig. S4B). Such co-transfer of ROS-producing 
properties to the cybrids along with the transfer of mtDNA with or without the mutation 
suggests that ROS overproduction is due to the G13997A mutation. ROS overproduction 
was also observed in the P29mtB82M and B82mtA11 cybrids (Fig. S4C). 
How does ROS overproduction regulate metastasis, and which nuclear genes (if any) 
are involved in this process? We have reported previously (22, 26) that A11 cells, but not 
P29 cells, show resistance to hypoxia-induced apoptosis, accompanied by upregulation of 
antiapoptotic MCL-1 (myeloid cell leukemia-1). Moreover, A11 cells showed higher 
expression levels of two genes associated with neoangiogenesis, HIF-1α (hypoxia-
inducible factor-1α) and VEGF (vascular endothelial growth factor), in comparison of P29 
cells (27). Thus, we focused here on the expression of these three nuclear-coded genes. We 
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found that upregulation of the MCL-1, HIF-1α, and VEGF was co-transferred when mutant 
mtDNA was transferred from A11 cells to the P29mtA11 and A11mtA11 cybrids. Down 
regulation of three genes was co-transferred when wild-type mtDNA was transferred from 
P29 cells to the P29mtP29 and A11mtP29 cybrids (Fig. 2). Therefore, the mutated mtDNA 
and the resultant complex I defects induce upregulation of the MCL-1, HIF-1α, and VEGF 
genes and are associated with high metastatic potential (Fig. S1B). Gene expression 
profiling to compare P29mtP29 with P29mtA11, and A11mtP29 with A11mtA11 showed 
consistent upregulation of other genes possibly related to metastasis in the cybrids with 
A11 mtDNA (Table S3), suggesting involvement of additional genes in the mtDNA-
mediated effects on metastasis.  
To obtain direct evidence that ROS overproduction caused by the mutated mtDNA 
from A11 cells is responsible for high metastatic potential, we treated the P29mtA11 
cybrids with ROS scavengers, and examined their effects on the amounts of ROS and on 
the expression of the genes and the phenotypes related to metastasis. N-acetylcysteine 
(NAC), which has been used as an anti-cancer agent in preclinical models, was used as one 
ROS scavenger. The results showed that treatment of the cybrids with NAC in cell culture 
reduced the amount of ROS (Fig. 3A) and downregulated MCL-1 (Fig. 3B). Moreover, pre-
treatment of the cybrids with NAC reduced their metastatic potential in two mouse models 
(Fig. 3C). Similar results were obtained by treatment with another ROS scavenger, Ebselen, 
which is a mimic of glutathione peroxidase (Fig. 3). Thus, ROS overproduction caused by 
the mutated mtDNA induces a high metastatic potential, at least in part, by upregulation of 
MCL-1.  This idea is supported by the finding that down-regulation of MCL-1 in 
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P29mtA11 cybrids by siRNA also suppressed their metastatic potential (Fig. S5). Moreover, 
NAC treatment suppressed the metastatic potential without reducing glycolytic activity (Fig. 
S6), suggesting that metastasis is not caused by upregulation of glycolysis.  
Contribution of mtDNA to tumor cell metastasis can be extended to human tumors, 
since the transfer of mtDNA from human breast cancer MDA-MB-231 cells expressing 
high metastatic potential into low metastatic HeLa cells induces complex I defects, 
increased ROS production, and high metastatic potential in HeLa cells (Fig. 4). These 
observations suggest that the mtDNA in MDA-MB-231 cells can promote metastasis, 
although we have not done the mtDNA sequencing. Therefore, the metastatic potential of 
all mouse and human tumor cell lines we examined was greatly enhanced by exchanging 
their endogenous mtDNA with mutant mtDNA that induces complex I-mediated ROS 
overproduction. Recent reports showed that a pathogenic mutation in the ATP6 gene of 
human mtDNA generated ROS and enhanced tumor growth (10, 11). However, in our 
experiments, the enhanced growth rate of primary tumors did not necessarily correlate with 
expression of the high metastatic potential in mouse tumors (Fig. S2B). 
This study partially resolves the debate on the relevance of mtDNA mutations in 
tumors (4-14) by showing that mutations in mtDNA can control the metastatic potential of 
certain tumor cells, but do not confer tumorigenic potential to non-transformed mouse 
NIH3T3 cells. Moreover, reversible regulation of metastasis by the exchange of mtDNA 
between P29 and A11 cells and by treatment with ROS scavengers suggests that metastasis 
of these cells is regulated by ROS-mediated reversible upregulation of nuclear genes, but 
not by ROS-mediated acceleration of genetic instability. The mtDNA-mediated reversible 
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control of metastasis, therefore, reveals a novel function of mtDNA, and suggests that in 
such cases ROS scavengers may be therapeutically effective in suppressing metastasis. 
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Table 1   Identification of pathogenic mutations by comparison of mtDNA sequences between low and high 
metastatic mouse tumor cells 
Mouse 
strain Cell lines Position Gene 
Amino 
acid 
change C57BL/6 P29 A11 L929  B82 B82M NIH/3T3
T6589C COI V421A T T T C C C T 
G9348A COIII V248I G G G A A A G 
T9461C ND3 Silent T C C C C C C 
9821-PolyA tRNAArg - 8A 9A 9A 10A 10A 10A 10A 
C11493A ND4 P443T C A A C C C C 
A13672T ND6 Silent A T T A A A A 
13885insC ND6 Frame-shift - - - - - C* - 
G13997A ND6 P25L G G A* G G G G 
Accession No. AY172335 EU312160 EU312161 AJ489607 EU315229 EU315228 AY999076
*   The G13997A mutation in ND6 is a missense mutation that changes the amino acid proline to leucine at a site that 
is highly conserved throughout vertebrates. The 13885insC mutation in ND6 is a frame-shift mutation that has 
been previously reported as a pathogenic mutation that induces significant complex I defects in some sublines of 
an L929 fibroblast cell line and A9 cells (see Materials and Methods). 
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Figure Legends 
Figure 1 Mitochondrial respiratory function of parental mouse cells and their 
trans-mitochondrial cybrids. 
(A) Comparison of respiratory complex activities between low and high metastatic 
tumor cell lines. P29 and A11 cells are low and high metastatic Lewis lung 
carcinoma cells, respectively; B82 and B82M cells are low and high metastatic 
fibrosarcoma cells, respectively; NM11 and LuM1 cells are low and high metastatic 
colon cancer cells, respectively (see Table S1). Respiratory complex I (NADH 
dehydrogenase), complex II (succinate dehydrogenase), and complex III 
(cytochrome c reductase) are components of the electron-transport chain located 
in the mitochondrial inner membrane. Mitochondrial respiratory function was 
examined by estimating their activities.  Since the complexes II+III activity is normal 
in the A11 and B82M cells, the reduced activity of complexes I+III exclusively 
observed in the A11 and B82M cells should represent complex I defects.  (B) 
Comparison of respiratory complex activities of the cybrids with mtDNA exchanged 
between low metastatic P29 and high metastatic A11 Lewis lung carcinoma cells. 
(C) Comparison of respiratory complex activities of the cybrids with mtDNA 
transferred from different types of tumor cells expressing high metastatic potential. 
Bars represent the mean ± s.d. (n = 3). *, P < 0.05, **, P < 0.01. 
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Figure 2 Reversible control of metastasis-related nuclear gene expression by 
mtDNA. 
(A) Expressions of nuclear-coded MCL-1 and HIF-1α, and (B) VEGF under 
normoxia (N) and hypoxia (H). As loading controls in the Western blots, we used β-
actin for MCL-1 and E2F-1 for HIF-1α (A). In (B), blue bars represent cybrids 
carrying mtDNA from P29 cells (P29mtP29 and A11mtP29), and red bars 
represent cybrids carrying mtDNA from A11 cells (A11mtA11 and P29mtA11).  
Bars represent the mean ± s.d. (n = 3). *, P < 0.01, **, P < 0.001. 
 
Figure 3 Suppression of metastasis by treatment of the P29mtA11 cybrids 
with ROS scavengers.  
(A) Effects of NAC and Ebselen treatments on the amounts of ROS. The 
P29mtA11 cybrids (1 × 106 cells) treated with 5 μM DCFH-DA were subjected to 
FACScan for quantitative estimation of ROS (H2O2). FACScan was carried out 
before (green) and after (yellow) 24 h treatment of the cybrids with 20 mM NAC or 
20 μM Ebselen.  (B) Effects of NAC and Ebselen treatments on MCL-1 expression.  
Western blot analysis of MCL-1 was carried out before and after the treatment of 
P29mtA11 cybrids with 20 mM NAC or 20 μM Ebselen for 4 days. β-Actin served 
as the loading control.  (C) Effects of NAC and Ebselen treatments on metastatic 
potential.  The P29mtA11 cybrids pretreated for 4 days with 20 mM NAC or with 20 
15 
μM Ebselen were injected into the tail vein of C57BL/6 mice to test the 
experimental metastatic potential. To examine the effect of NAC administration on 
spontaneous metastatic potential, P29mtA11 cybrids without NAC pretreatment 
were injected subcutaneously into C57BL/6 mice, which subsequently received 10 
mg/ml NAC in drinking water ad libitum. Bars represent the mean ± s.d. (n = 3). *, 
P < 0.05, **, P < 0.01. 
 
Figure 4  Induction of high metastatic potential in HeLa cells by introduction 
of mtDNA from human breast adenocarcinoma MDA-MB-231 cells expressing 
high metastatic potential.  
Induction of (A) complex I defects, (B) ROS overproduction, and (C) high 
metastatic potential in the Hemt231 cybrids.  HemtHe, HemtHe cybrids carrying 
nuclear DNA from ρ0 HeLa cells and mtDNA from wild-type HeLa cells; Hemt231, 
Hemt231 cybrids carrying nuclear DNA from ρ0 HeLa cells and mtDNA from MDA-
MB-231 cells. Bars represent the mean ± s.d. (n = 3). *, P < 0.05. 
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